News
The European Union’s health regulator has lifted the temporary restriction on the use of French drugmaker Valneva’s ...
BioNTech has agreed to buy another specialist in mRNA medicines, fellow German biotech CureVac, for around $1.25 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback